EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
.png)
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients.
The European Academy of Paediatrics has warned the EU to correct a new law that inadvertently prevents the provision of essential medical devices for children, citing unintended consequences of the EU Medical Devices Regulation (MDR).
In a letter sent on June 27, 2023 to EU Health Commissioner Stella Kyriakides, the Academy, along with 22 other medical associations, cited that the law that requires companies to recertify their products. Though the deadline for companies to achieve this has been extended until 2027/2028, reports from doctors claim that the new legislation has caused shortages of certain lifesaving equipment, especially those from small drug device companies that cannot afford the new compliance procedure, and that the extension has not solved the issue for these companies. All drug device companies are required by the new law to sign a contract by September 2024 with a notified body to begin the recertification process. The law came into effect in 2021 with the goal of preventing health scandals.
The group cited one particular company that received invoices from a notified body of over EUR €800,000 for a single device to be assessed. The device is already on the market for, at the most, 5 years of market access. At nearly 150 times more costly than the process in the United States for the same device, the group warns that similar situations may cause lifesaving drug devices to disappear from the market. In the letter, the associated groups urged for access protection of certain drug devices for children and patients with rare diseases. They reported that a specific type of catheter utilised in lifesaving surgery on newborns with heart defects has become unavailable due to the law, as well as shortages in dialysis machines for children with kidney disease.
The group emphasised the dire consequences of such shortages in their letter, stating “This will result in an avoidable risk of death and serious injury – not as a consequence of unsafe medical devices, but as a consequence of [the] disappearance of devices due to unforeseen effects of the EU Medical Devices Regulation.”
Source: EU must prevent medical devices for children from disappearing, say doctors groups [Accessed June 28, 2023] https://www.reuters.com/business/healthcare-pharmaceuticals/eu-must-prevent-medical-devices-children-disappearing-say-doctors-groups-2023-06-27/
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance